evonetix Stock

evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA.

Sign up today and learn more about evonetix Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About evonetix Stock

We are a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Funding History

January 2018$12.3M
July 2018$1.3M


Chief Technology Officer

Matthew Hayes


Ray Edgson

Chief Scientific Officer

Joseph Brennan


Tim Brears

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: